Skip to main content
Premium Trial:

Request an Annual Quote

Biolytical Gets Canadian Authorization for Point-of-Care COVID-19 Antigen Test

NEW YORK — Biolytical Laboratories said on Monday that it has received authorization from Canadian regulators for its point-of-care iStatis COVID-19 Antigen Test.

According to the British Columbia-based firm, the lateral flow assay is portable, provides results within 15 minutes, and has demonstrated 91.4 percent sensitivity and 100 percent specificity.

In November, Biolytical received Canadian authorization for a one-minute COVID-19 antibody test that uses fingerstick blood samples. That test was developed with funding from the National Research Council of Canada Industrial Research Assistance Program.